Cancer News
OncoLink Cancer News - HealthDay


Lymphoseek Approved for Diagnosing Cancer Severity

Friday, June 13, 2014 (Last Updated: 06/16/2014)

FRIDAY, June 13, 2014 (HealthDay News) -- U.S. Food and Drug Administration approval for the Lymphoseek imaging agent (technetium 99m tilmanocept) has been expanded to determine if squamous cell carcinoma has spread to the head and neck, and to what extent, the FDA said Friday.

The injected agent was first approved in 2013 to help doctors identify lymph nodes associated with breast cancer or melanoma skin cancer, the agency said in a news release.

For the newly approved use, the agent was evaluated in a clinical study of 85 people with squamous cell carcinoma of the lip, mouth, or skin. The most common side effects noted were injection-site pain and irritation.

Lymphoseek is marketed by Navidea Biopharmaceuticals, based in Dublin, Ohio.

More Information

Specialties Hematology & Oncology
Family Practice
Internal Medicine
Nursing
OBGYN & Women's Health

Health News Copyright © 2014 HealthDay. All rights reserved.


I Wish You Knew

Common myths about pain medication and pain control

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More